Immunocore Holdings plc (IMCR): Price and Financial Metrics


Immunocore Holdings plc (IMCR): $60.47

1.52 (+2.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMCR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMCR POWR Grades

  • IMCR scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.93% of US stocks.
  • The strongest trend for IMCR is in Stability, which has been heading down over the past 179 days.
  • IMCR ranks lowest in Momentum; there it ranks in the 4th percentile.

IMCR Stock Summary

  • IMCR's went public 1.82 years ago, making it older than merely 7.75% of listed US stocks we're tracking.
  • With a price/sales ratio of 23.2, IMMUNOCORE HOLDINGS PLC has a higher such ratio than 94.73% of stocks in our set.
  • Revenue growth over the past 12 months for IMMUNOCORE HOLDINGS PLC comes in at 233.9%, a number that bests 96.33% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to IMMUNOCORE HOLDINGS PLC, a group of peers worth examining would be WATT, ATOM, CRNC, AIP, and SDGR.
  • Visit IMCR's SEC page to see the company's official filings. To visit the company's web site, go to www.immunocore.com.

IMCR Stock Price Chart Interactive Chart >

Price chart for IMCR

IMCR Price/Volume Stats

Current price $60.47 52-week high $69.06
Prev. close $58.95 52-week low $18.43
Day low $59.00 Volume 324,100
Day high $61.20 Avg. volume 247,794
50-day MA $53.03 Dividend yield N/A
200-day MA $40.78 Market Cap 2.66B

Immunocore Holdings plc (IMCR) Company Bio


Immunocore Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops and commercializes a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune diseases. Immunocore Holdings serves customers in the United Kingdom and the United States.


IMCR Latest News Stream


Event/Time News Detail
Loading, please wait...

IMCR Latest Social Stream


Loading social stream, please wait...

View Full IMCR Social Stream

Latest IMCR News From Around the Web

Below are the latest news stories about IMMUNOCORE HOLDINGS PLC that investors may wish to consider to help them evaluate IMCR as an investment opportunity.

Immunocore Holdings PLC Sponsored ADR (IMCR) is on the Move, Here's Why the Trend Could be Sustainable

Immunocore Holdings PLC Sponsored ADR (IMCR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Yahoo | November 28, 2022

uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

Yahoo | November 23, 2022

Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation

Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery.

Yahoo | November 23, 2022

How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 28%

The consensus price target hints at a 27.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 23, 2022

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat

Yahoo | November 23, 2022

Read More 'IMCR' Stories Here

IMCR Price Returns

1-mo 5.83%
3-mo 16.51%
6-mo 84.92%
1-year 68.02%
3-year N/A
5-year N/A
YTD 76.61%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6708 seconds.